Antonio di Stasi, MD
Hematology & Oncology · Birmingham, ALNPI 1801211958
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,040 of the $2,401 with a category attached, or 85.0%. Medexus Pharma, Inc. accounts for 85.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $2,066 and has fallen 96.2% since, to $77 in 2025. That places this record below the midpoint for hematology & oncology clinicians in AL, where the typical reported total is $7,159.
Across 9 payments — averaging $266.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medexus Pharma, Inc.$2K
- Jazz Pharmaceuticals Inc.$190
- Astellas Pharma Global Development$49
- Johnson & Johnson$33
- AstraZeneca$27
- Genetix Biotherapeutics Inc$26
- plus $37 from 2 others
Across 91 payments — averaging $14,003 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Servier Bioinnovation$892K
- Astellas Pharma Global Development$121K
- Agios Pharmaceuticals, Inc.$81K
- Syndax Pharmaceuticals, Inc.$79K
- Merck$32K
- Takeda Pharmaceuticals U.S.A., Inc.$28K
- plus $41K from 6 others
What the payments were for
- Consulting fees$2,04085%
- Food & beverage$36115%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medexus Pharma, Inc. | 1 | $2,040 |
| Jazz Pharmaceuticals Inc. | 2 | $190 |
| Astellas Pharma Global Development | 1 | $49 |
| Johnson & Johnson | 1 | $33 |
| AstraZeneca | 1 | $27 |
| Genetix Biotherapeutics Inc | 1 | $26 |
| AbbVie | 1 | $19 |
| Sobi, Inc | 1 | $18 |
How this compares
$2,401 in reported general payments places this provider in the 25th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 21 | $304,034 |
| Posaconazole | 16 | $18,466 |
| Ondansetron Hcl | 16 | $2,510 |
| Oxycodone Hcl | 38 | $501 |
| Acyclovir | 40 | $476 |
| Gabapentin | 42 | $467 |
| Ondansetron OdtOndansetron | 17 | $284 |
| Magnesium Sulfate | 23 | $280 |
| Alprazolam | 21 | $156 |
| Pantoprazole Sodium | 16 | $102 |
| Tramadol Hcl | 12 | $42 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Birmingham
- Amitkumar MehtaBirmingham$683K
- Pankit VachhaniBirmingham$545K
- Luciano CostaBirmingham$409K
- Khaleel AshrafBirmingham$379K
- Michael BirrerBirmingham$302K
- Rudolph NavariBirmingham$254K
- Mayur NarkhedeBirmingham$193K
- Midhun MallaBirmingham$144K
- Robert ConryBirmingham$143K
- David MooneyBirmingham$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.